Pulmonary Arterial Hypertension: Real-World Applications of New Therapies and Management Strategies

This activity was originally presented live at Asembia's AXS25 Summit in Las Vegas, Nevada on April 28, 2025.

Program Description
The detection, stratification, and management of pulmonary arterial hypertension (PAH) has experienced significant progress, leading to updated evidence-based recommendations and revised definitions based on greater knowledge of pathophysiologic and diagnostic mechanisms of PAH. Despite better understanding of PAH pathophysiology, guidelines, and pharmacologic options, challenges in PAH management include early diagnosis, early initiation of treatment, and underutilization of guidelines. Additionally, questions about the optimization of monotherapy, add-on, and combination therapy remain, as they are dictated by prior hemodynamic criteria and functional status. Pharmacists play a crucial role in reducing the burden of disease for patients with PAH, and they must be familiar with disease severity and efficacy and safety data for established and emerging treatments to prevent PAH disease progression, improve symptoms, and optimize patient outcomes. This session will examine the current and emerging treatment landscape of PAH and how management approaches can help specialty pharmacists provide patient-specific counseling, navigate therapy recommendations, and improve treatment access for patients with PAH. To illustrate real-world application of these concepts and updated guidelines in treatment decision-making, patient case video vignettes will be presented to facilitate interactive learning and enhance understanding of patient-specific needs and treatment decisions in PAH management.

Target Audience: Managed care and specialty pharmacists

Type of Activity: Application
Release date: May 6, 2025
Expiration date: May 6, 2026
Learner level: Intermediate
Time to complete activity: 1.5 hours
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Apply knowledge of pulmonary arterial hypertension (PAH) pathophysiology to uncover the impact of PAH on patients' quality of life
• Employ recommendations from current guidelines for the management of PAH in the development of treatment plans for patients with PAH, including those with cardiovascular comorbidities
• Identify opportunities for specialty pharmacists to reduce treatment gaps for patients with PAH, including treatment initiation, dose optimization strategies, and monitoring response to treatment

Pharmacy Times Continuing Education^™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEU) under the ACPE universal activity number 0290-0000-25-124-H01-P. The activity is available for CE credit through May 6, 2026.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, view the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Disclosures

Zachary R. Smith, PharmD, FCCM, FCCP, BCPS, BCCCP, has the following relevant financial relationships with commercial interests to disclose:

Advisory board: Merck & Co, Inc

The following contributors have no relevant financial relationships with commercial interests to disclose:

Faculty

Kerry Mello-Parker, PharmD, MBA

Pharmacy Times Continuing Education^™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh, MBA; Adam C. Welch, PharmD, MBA, FAPhA; Crissy Wilson; Susan Pordon; Brianna Winters; Chloe Taccetta, and Rebecca Green.

At least one anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose.

Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms